Immunologically effective poly(D-lactic acid) nanoparticle enhances anticancer immune response  

作　　者：Weiguo Xu Yuanzhen Su Yang Ma Qi Wei Jiazhen Yang Xiuli Zhuang Jianxun Ding Xuesi Chen 

机构地区：[1]School of Applied Chemistry and Engineering,University of Science and Technology of China,Hefei 230026,China [2]Key Laboratory of Polymer Ecomaterials,Changchun Institute of Applied Chemistry,Chinese Academy of Sciences,Changchun 130022,China [3]Department of Thoracic Surgery,China-Japan Union Hospital of Jilin University,Changchun 130033,China

出　　处：《Science China Chemistry》2023年第4期1150-1160,共11页中国科学（化学英文版）

基　　金：supported by the National Natural Science Foundation of China(52273159,52273158,U21A2099,52173149,52073280,52022095,51973216,51873207,51833010);the Science and Technology Development Program of Jilin Province(20210509005RQ,20210504001GH,20200404182YY);the“Special Project for City-Academy Scientific and Technological Innovation Cooperation”of Changchun(21SH14);the Youth Innovation Promotion Association of Chinese Academy of Sciences(2019230)。

摘　　要：Chiral materials with the same atomic compositions exhibit different chemical,physical,and biological properties because of their distinct spatial structures.Herein,a chiral strategy was proposed to develop poly(lactic acid)(PLA)nanoparticle as an efficient nanoadjuvant to activate adaptive anticancer immunity.Two chiral nanovaccines were prepared by directly mixing amino-terminated PLA(PLLA-NH2 or PDLA-NH2)with the model protein antigen ovalbumin(OVA).After being injected into mice subcutaneously,both nanovaccines efficiently migrated to the lymph nodes to initiate the sequential anticancer immune responses.Compared with the PLLA nanovaccine(PLLA-OVA),the PDLA one(PDLA-OVA)contributed to more robust dendritic cell(DC)maturation,antigen presentation,and T lymphocyte activation.In addition to the activation of cellular immunity,PDLA-OVA also triggered a more vigorous activation of humoral immunity,which induced the production of more anti-OVA immunoglobulin G(IgG)than PLLA-OVA.When used as prophylactic or therapeutic nanovaccine toward murine melanoma models,PDLA-OVA triggered more potent adaptive anticancer immune responses that more effectively inhibited the cancer genesis and progression,indicating the significant potential of immunologically effective PDLA nanoadjuvant in cancer immunotherapy.

关 键 词：poly(D-lactic acid) chiral nanomaterial immune nanoadjuvant NANOVACCINE cancer immunotherapy 

分 类 号：R318.08[医药卫生—生物医学工程] TB383.1[医药卫生—基础医学]